ProPhase Labs, Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
ProPhase Labs, Inc. (PRPH) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-06-01
- ProPhase Labs, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-12-31 was $0.00.
- ProPhase Labs, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-09-30 was $0.00.
- ProPhase Labs, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-06-30 was $0.00.
- ProPhase Labs, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2025-03-31 was $0.00.
- ProPhase Labs, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was $0.00.
- ProPhase Labs, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was -$18.00K, a 181.82% decline from fiscal 2023.
- ProPhase Labs, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2023 was $22.00K.
- ProPhase Labs, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2022 was -$354.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $0.00 derived: sum of 2 quarters · filed 2026-06-01 | $0.00 derived: sum of 3 quarters · filed 2026-06-01 | $0.00 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2025-11-19 | $0.00 10-Q · filed 2025-11-19 | $0.00 derived: sum of 4 quarters · filed 2026-06-01 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-06-01 | $0.00 derived: sum of 4 quarters · filed 2026-06-01 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-20 | $0.00 derived: sum of 2 quarters · filed 2026-06-01 | $0.00 derived: sum of 3 quarters · filed 2026-06-01 | $0.00 derived: sum of 4 quarters · filed 2026-06-01 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $0.00 derived: sum of 2 quarters · filed 2026-06-01 | $0.00 derived: sum of 3 quarters · filed 2026-06-01 | -$18.00K 10-K · filed 2026-06-01 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2025-11-19 | -$18.00K 10-Q · filed 2025-11-19 | $1.00K derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$18.00K 10-Q · filed 2025-08-13 | $1.00K derived: sum of 3 quarters · filed 2025-08-13 | $112.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$18.00K 10-Q · filed 2025-05-20 | $1.00K derived: sum of 2 quarters · filed 2025-05-20 | $112.00K derived: sum of 3 quarters · filed 2025-05-20 | $111.00K derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $130.00K derived: sum of 2 quarters · filed 2025-04-01 | $129.00K derived: sum of 3 quarters · filed 2025-04-01 | $22.00K 10-K · filed 2025-04-01 |
| 2023-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $110.00K derived: sum of 2 quarters · filed 2024-11-13 | $3.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$108.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$107.00K 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | -$354.00K 10-K · filed 2024-03-29 | |||
| 2021-12-31 | -$165.00K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |